创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology:Key Benefits of the InnoModels Humanized Model of the Biological Immune System

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-07 14:20
  • Views:

(Summary description)In biomedical research, experimental models that can accurately simulate human physiological mechanisms are essential. The InnoModels Biotechnology Humanized Model of the Immune System (TMIMS) was born to meet this need, and it has shown great potential in the fields of disease research, drug development and immunotherapy with its unique advantages.

InnoModels Biotechnology:Key Benefits of the InnoModels Humanized Model of the Biological Immune System

(Summary description)In biomedical research, experimental models that can accurately simulate human physiological mechanisms are essential. The InnoModels Biotechnology Humanized Model of the Immune System (TMIMS) was born to meet this need, and it has shown great potential in the fields of disease research, drug development and immunotherapy with its unique advantages.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-04-07 14:20
  • Views:
Information

In biomedical research, experimental models that can accurately simulate human physiological mechanisms are essential. The InnoModels Biotechnology Humanized Model of the Immune System (TMIMS) was born to meet this need, and it has shown great potential in the fields of disease research, drug development and immunotherapy with its unique advantages.
First of all, the main advantage of the humanized immune system model is its highly humanized characteristics. Traditional animal models differ greatly from humans in terms of their immune systems, which leads to uncertainty and unpredictability in experimental results. In contrast, the humanized model of immune system of InnoModels Biotechnology introduces key components of the human immune system into the animal model through gene editing and cell transplantation, making the whole model closer to humans in terms of immune response, composition of immune cells, and the development of immune-related diseases.

 


Secondly, the model provides a more realistic experimental environment for disease research. Since the model has a humanized immune system, researchers can study various immune-related diseases, such as autoimmune diseases, infectious diseases and tumors, under conditions closer to human physiology. This not only contributes to a deeper understanding of the pathogenesis of diseases, but also provides more precise strategies and methods for disease prevention and treatment.
In addition, humanized models of the immune system have shown unique advantages in drug screening and immunotherapy. By simulating the response of the human immune system, the model can more accurately predict the efficacy and side effects of drugs in the human body, thus accelerating the drug development process. At the same time, the model can also be used to evaluate the effectiveness of immunotherapy strategies, providing strong support for personalized treatment and precision medicine.
Last but not least, the humanized model of the immune system is highly flexible and controllable. Researchers can simulate immune system responses in different disease states by adjusting factors such as gene expression, cellular composition and immune stimulation in the model. This flexibility allows researchers to customize personalized experimental models to better meet different research needs.
In summary, InnoModels' humanized model of the immune system provides a powerful tool for biomedical research with its highly humanized properties, realistic experimental environment, potential for drug screening and immunotherapy, and flexibility and controllability. With the continuous progress of technology and the expansion of application fields, we have reason to believe that such models will play an even more important role in the future and make greater contributions to human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司